Claims for Patent: 6,187,319

Summary for Patent: 6,187,319

Title:	Cross-protective rotavirus vaccine
Abstract:	A method of producing an effective immune response in an animal against a first rotavirus, by (1) identifying an animal susceptible to or having a first rotavirus infection; and (2) administering to the animal an isolated VP6 polypeptide of a second rotavirus sufficient to produce an effective immune response against the first rotavirus, the second rotavirus capable of infecting a different species than the first rotavirus.
Inventor(s):	Herrmann; John E. (Northborough, MA), Lu; Shan (Northborough, MA)
Assignee:	University of Massachusetts (Boston, MA)
Application Number:	09/088,216
Patent Claims:	1. A method of producing a protective immune response in a bird or mammal against a first rotavirus, the method comprising: identifying a bird or mammal susceptible to or having a first rotavirus infection; administering to the bird or mammal an isolated VP6 polypeptide of a second rotavirus sufficient to produce a protective immune response against the first rotavirus, the second rotavirus capable of infecting a different species than the first rotavirus. 2. The method of claim 1, wherein the isolated VP6 polypeptide of the second rotavirus is administered to the bird or mammal via an expression vector comprising a nucleotide sequence encoding the VP6 polypeptide of the second rotavirus. 3. The method of claim 2, wherein the expression vector is a DNA plasmid. 4. The method of claim 2, wherein the expression vector is encapsulated in a microparticle. 5. The method of claim 4, wherein the microparticle comprises poly(lactide-co-glycolide). 6. The method of claim 2, wherein the expression vector further comprises a cytomegalovirus intron A transcriptional regulatory sequence and a cytomegalovirus enhacer and promoter sequence operably linked to the sequence encoding the VP6 polypeptide of the second rotavirus. 7. The method of claim 2, wherein the expression vector is administered orally. 8. The method of claim 1, wherein the bird or mammal is a mammal selected from the group consisting of cows, pigs, and horses. 9. The method of claim 1, wherein the bird or mammal is a human. 10. The method of claim 9, wherein the first rotavirus is capable of infecting humans. 11. The method of claim 10, wherein the second rotavirus is capable of infecting cows. 12. The method of claim 1, wherein the VP6 polypeptide cross-reacts with antibodies produced from the bird or mammal when infected with the first rotavirus. 13. A method of producing a protective immune response in a individual against a human rotavirus, the method comprising: identifying an individual susceptible to or having a human rotavirus infection; administering to the individual a DNA plasmid expression vector comprising a sequence encoding a VP6 polypeptide of a non-human rotavirus, the VP6 polypeptide expressed from the DNA plasmid in vivo being sufficient to produce a protective immune response in the individual against the human rotavirus. 14. The method of claim 13, wherein the DNA plasmid expression vector is administered as a microparticle. 15. The method of claim 14, wherein the microparticle comprises poly(lactide-co-glycolide). 16. The method of claim 13, wherein the non-human rotavirus is capable of infecting a mammal selected from the group consisting of a pig, cow, or horse. 17. The method of claim 16, wherein the mammal is a cow. 18. The method of claim 13, wherein the VP6 polypeptide cross-reacts with antibodies produced from the individual when infected with the human rotavirus. 19. A method of producing a protective immune response in a bird or mammal of a first species against a first rotavirus, the method comprising: identifying a bird or mammal of a first species susceptible to or having a first rotavirus infection; administering to the bird or mammal an isolated VP6 polypeptide of a second rotavirus sufficient to produce a protective immune response against the first rotavirus, the second rotavirus capable of infecting a second species different from the first species and incapable of infecting the first species. 20. The method of claim 19, wherein the isolated VP6 polypeptide of the second rotavirus is administered to the bird or mammal via an expression vector comprising a nucleotide sequence encoding the VP6 polypeptide of the second rotavirus. 21. The method of claim 20, wherein the expression vector is a DNA plasmid. 22. The method of claim 21, wherein the expression vector is encapsulated in a microparticle. 23. The method of claim 22, wherein the microparticle comprises poly(lactide-co-glycolide). 24. The method of claim 20, wherein the expression vector further comprises a cytomegalovirus intron A transcriptional regulatory sequence and a cytomegalovirus enhacer and promoter sequence operably linked to the sequence encoding the VP6 polypeptide of the second rotavirus. 25. The method of claim 20, wherein the expression vector is administered orally. 26. The method of claim 19, wherein the bird or mammal is a mammal selected from the group consisting of cows, pigs, and horses. 27. The method of claim 26, wherein the bird or mammal is a human.

Details for Patent 6,187,319

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26